HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
HUTCHMED (China) LimitedNASDAQ: HCM
EBITDA · Q2 FY2025 · quarter ended Jun 2025
EBITDA turns positive
Q2 FY2025 EBITDA was $1.3M, compared with -$10.63M a year earlier. Trailing-twelve-month EBITDA was -$7.49M.
Context
- EBITDA amounted to 7.5% of revenue in FY2025, up 2.5 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 16 analysts of $92.11M (+322.6%) for the fiscal year ending Dec 2026, a step up from the -31.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2025
- $1.3M+0.0% QoQ
- Last fiscal yearDec 2025
- -$41.38M-31.9% YoY
- LTMJun 2025
- -$7.49M+93.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +112.2% | -925.1% | -1037.3 pp |
| 1 year | -31.9% | +322.6% | +354.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (41.38M) USD
- Year-over-year change
- -31.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.38M) | -31.9% |
| FY2024 | 2024-12-31 | (31.36M) | -218.0% |
| FY2023 | 2023-12-31 | 26.58M | +106.6% |
| FY2022 | 2022-12-31 | (401.11M) | -92.9% |
| FY2021 | 2021-12-31 | (207.96M) | — |
EBITDA vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +93.2% is the 2nd highest of 9, against a peer median of +20.8%.
- EBITDA amounts to 1.2% of revenue for HCM, versus a peer median of 40.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.07B USD | +52.6% | +43.2% | 35.5% | |
| LTM Jun 2026 | $1.22B USD | — | -43.3% | 29.5% | |
| LTM Jul 2026 | $1.05B USD | +28.1% | +53.4% | 43.0% | |
| LTM Sep 2026 | $99.55M USD | +154.3% | — | 7.3% | |
| LTM Jun 2025 | -$7.49M USD | +93.2% | — | 1.2% | |
| LTM Jun 2024 | -$63.57M USD | — | — | 979.5% | |
| LTM Mar 2026 | -$135.46M USD | +55.2% | — | 60.1% | |
| LTM Jun 2026 | -$168.8M USD | +13.6% | — | 37.5% | |
| LTM Jun 2026 | -$419M USD | -48.6% | — | 358.1% | |
| LTM Jun 2026 | -€941.06M EUR | -2167.6% | — | 35.6% | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥1.1B CNY | -360.8% | — | 196.1% |
| Peer median (excluding HCM) | — | +20.8% | +43.2% | 40.3% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 356.13M | 426.41M | 838M | 630.2M | 549.96M |
| Cost of Revenue | 258.23M | 311.1M | 384.45M | 348.88M | 337.24M |
| Gross Profit | 97.89M | 115.31M | 453.55M | 281.32M | 212.72M |
| Gross Margin | 27.5% | 27.0% | 54.1% | 44.6% | 38.7% |
| Research & Development | 207.45M | 267.59M | 303.06M | 213.37M | 164.15M |
| Selling, General & Admin | 127.13M | 136.11M | 133.18M | 112.91M | 103.3M |
| Operating Expenses | 426.21M | 523M | 436.23M | 321.93M | 267.45M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| EBITDA | (207.96M) | (401.11M) | 26.58M | (31.36M) | (41.38M) |
| EBITDA Margin | -58.4% | -94.1% | 3.2% | -5.0% | -7.5% |
| Operating Income | (328.32M) | (409.77M) | 18.38M | (43.71M) | (54.73M) |
| Operating Margin | -92.2% | -96.1% | 2.2% | -6.9% | -10.0% |
| Interest Income | 2.08M | 9.6M | 36.15M | 40.08M | 50.01M |
| Interest Expense | 592K | 652K | 759K | 2.87M | 2.87M |
| Other Income / Expenses | 173.19M | 51.52M | 87.23M | 89.07M | 577.45M |
| Income Before Tax | (155.33M) | (360.24M) | 105.6M | 45.36M | 522.72M |
| Pre-Tax Margin | -43.6% | -84.5% | 12.6% | 7.2% | 95.0% |
| Income Tax Expense | 11.92M | (283K) | 4.51M | 7.19M | 63.78M |
| Net Income | (194.65M) | (360.84M) | 100.78M | 37.73M | 458.12M |
| Net Margin | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
| EPS (Basic) | (1.25) | (2.15) | 0.60 | 0.22 | 2.65 |
| EPS (Diluted) | (1.25) | (2.15) | 0.60 | 0.22 | 2.60 |
| Weighted Avg Shares | 158.54M | 169.43M | 169.93M | 171.07M | 171.66M |
| Weighted Avg Shares (Diluted) | 158.54M | 169.43M | 173.84M | 174.57M | 174.58M |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.